Xenetic Biosciences, Inc. — 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. Although the request references 2019 Q4, this 10-K reports full-year results; it notes that $17,066 of Takeda-related royalty revenue was recognized in the fourth quarter. The filing was signed March 26, 2020.
Business context
Xenetic is a clinical-stage biopharmaceutical company with no approved products. Its primary strategic focus shifted to XCART, a personalized CAR T platform intended to target patient-specific B-cell lymphoma receptors. The company acquired the technology in July 2019. PolyXen remains available for partner licensing, while internal work on other programs was limited by capital constraints. XBIO-101 Phase 2 enrollment ended in March 2019 and further development was suspended.
Key financial results and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $17,066 | $0 |
| Research and development expense | $4.89 million | $2.88 million |
| General and administrative expense | $4.73 million | $4.39 million |
| Goodwill impairment | $3.28 million | $0 |
| Operating loss | $12.89 million | $7.28 million |
| Net loss | $12.78 million | $7.30 million |
| Net loss applicable to common stockholders | $18.06 million | $7.30 million |
| Basic and diluted loss per share | $6.33 | $9.66 |
| Cash and cash equivalents at year-end | $10.37 million | $0.57 million |
| Net cash used in operating activities | $6.40 million | $6.46 million |
| Working capital | $9.7 million | $(0.4) million |
Revenue was solely royalty revenue from Takeda’s sublicense of PolyXen-related patents; it is too small to support meaningful margin analysis. R&D increased primarily because $3.03 million of XCART acquired in-process R&D was expensed. Excluding that item, R&D declined 35.6%. G&A included about $1.1 million of XCART transaction costs; excluding those costs, it declined 17.4%.
Cash from financing activities was $16.13 million, principally from March and July 2019 equity offerings. The July offering produced approximately $13.4 million of net proceeds. Total assets were $21.55 million and total liabilities were $4.33 million at year-end. Current liabilities were $1.42 million. The balance sheet reports no conventional interest-bearing corporate debt; the company did, however, make a related-party loan to Pharmsynthez of up to $500,000 at 10% interest, secured by specified collateral.
A $5.28 million deemed dividend related to Series B preferred-stock down-round provisions increased the loss applicable to common stockholders, but did not increase reported net loss. Goodwill was written off in full; the $9.24 million indefinite-lived OncoHist intangible was not impaired in 2019.
Material changes and management outlook
- The July 2019 XCART acquisition was accounted for as an asset acquisition. Xenetic issued shares and recorded $3.03 million of acquired R&D expense and about $1.1 million of transaction costs.
- The company completed a 1-for-12 reverse stock split in June 2019 and increased authorized common shares. Financing and warrant exercises materially expanded shares outstanding; approximately 2.2 million purchase warrants were exercised cashlessly during 2019.
- Management said the March and July financings, together with existing resources, were expected to fund operations through mid-2021. It also expects to need additional capital over the longer term. The filing states that substantial doubt exists about the company’s ability to continue as a going concern.
- Management intends to prioritize XCART development, potentially through an academic collaboration, and pursue licensing or collaboration opportunities for other technology. No firm XCART clinical or regulatory timetable is provided in the filing text.
- Takeda’s covered-product sales began in 2019 and generated the first sublicense royalty revenue. Management cautioned that further milestone or royalty payments are uncertain and not expected in the near term, if at all, apart from royalties already arising under the Takeda sublicense.
Risks, contingencies, and unusual items
- XCART is early-stage and the business substantially depends on successful development, regulatory approval, manufacturing arrangements, and eventual commercialization. No XCART manufacturing agreement was in place at year-end.
- Clinical, regulatory, and financing risks are significant; patient-enrollment and retention problems already led to suspension of XBIO-101. Existing CAR T therapies can cause severe or fatal toxicities, and XCART’s proposed safety advantages remain to be demonstrated clinically.
- The company has four full-time employees and relies heavily on outside service providers, collaborators, and manufacturers. It has no in-house research or manufacturing facilities.
- Pharmsynthez is a significant stockholder and related party. Related-party transactions included a $350,000 sponsored research payment, of which about $195,000 remained prepaid at year-end, and the loan of up to $500,000 described above.
- Series B preferred stock has a full-ratchet anti-dilution provision and conversion and liquidation preferences. Further equity or equity-linked financing may dilute common stockholders. Outstanding preferred stock, warrants, options, and awards also represent potential dilution.
- The filing identifies no material litigation at December 31, 2019. The independent auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to ICFR.
Important facts for investors to verify
- Whether cash, spending, and any subsequent financing support operations beyond management’s stated mid-2021 runway.
- Progress toward an academic collaboration, technology transfer, manufacturing plan, and regulatory engagement for XCART, including any IND timetable.
- Takeda sublicense royalty reports, sales trends, and the extent to which royalty revenue can become material.
- The amount and terms of any Pharmsynthez loan advances outstanding, repayment status, and collectability; also review the related-party research arrangement.
- Potential dilution from preferred-stock conversion, warrants, options, and future capital raises, including the Series B anti-dilution terms.
- Whether the $9.24 million OncoHist intangible remains recoverable given that development is on hold, and whether future impairment or going-concern developments alter reported asset values.